Skip to main content

Cancer Rates Among Individuals with Loop Diuretics Exposure: A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
bumetanide
loop diuretics
Description

In this report, we conducted a sensitivity analyses examining the rates of cancer among individuals exposed to loop diuretics in the Sentinel Distributed Database (SDD).

The study period includes data from January 1, 2000 to February 28, 2022. We distributed this request to six Sentinel Data Partners on January 20, 2023.

Deliverables (1)
Sentinel Modular Program Report: Cancer Rates Among Individuals with Loop Diuretics Exposure: A Descriptive Analysis
Additional Details
FDA Center
CDER
Time Period
January 1, 2000 - February 28, 2022
Analysis Type
Descriptive
Population / Cohort
All individuals
Data Sources
Sentinel Distributed Database (SDD)
Related Links
Sentinel Drug Study: Bumex (Bumetanide) & Nitrosamine Impurity
Sentinel Drug Analysis: Utilization of Loop Diuretics: A Descriptive Analysis
Sentinel Drug Analysis: Incident and Prevalent Use of Loop Diuretics: A Descriptive Analysis